Perspectives on adherence and persistence with oral medications for cancer treatment

Abstract

Ensuring persistence, continuing treatment for the prescribed duration, and adherence-taking medication as prescribed-have been challenges for management of patients with oral cancer and for health care cost containment in real-world settings.

Figures

Figure 1.

The patients who persisted with letrozole either continued therapy (54%) or had a therapy gap but reinitiated treatment by the end of the year (23%; data on file, Novartis, East Hanover, NJ).